一种人肿瘤坏死因子α抑制剂。
A human inhibitor of tumor necrosis factor alpha.
作者信息
Seckinger P, Isaaz S, Dayer J M
机构信息
Department of Medicine, University Hospital, Geneva, Switzerland.
出版信息
J Exp Med. 1988 Apr 1;167(4):1511-6. doi: 10.1084/jem.167.4.1511.
Abstract
Urine of some febrile patients exhibits a TNF-alpha inhibitory activity (TNF-alpha INH), sensitive to heat and trypsin, with an apparent mol wt of 40-60 X 10(3) and a pI range of 5.5-6.1. As for the Il-1 INH, the TNF INH activity involves a competitive mechanism of action suggesting the existence of a family of negative feedback-regulating molecules interfering with cytokines actions.
摘要
一些发热患者的尿液表现出对热和胰蛋白酶敏感的肿瘤坏死因子-α抑制活性（TNF-α INH），其表观分子量为40 - 60×10³，等电点范围为5.5 - 6.1。至于白细胞介素-1抑制物（Il-1 INH），TNF抑制活性涉及一种竞争性作用机制，提示存在一族干扰细胞因子作用的负反馈调节分子。
相似文献
1
A human inhibitor of tumor necrosis factor alpha.一种人肿瘤坏死因子α抑制剂。
J Exp Med. 1988 Apr 1;167(4):1511-6. doi: 10.1084/jem.167.4.1511.
2
Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.一种肿瘤坏死因子α（TNF-α）抑制剂的特性：与TNF受体免疫交叉反应性的证据。
Proc Natl Acad Sci U S A. 1990 Jul;87(13):5188-92. doi: 10.1073/pnas.87.13.5188.
3
Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.一种特异性肿瘤坏死因子α抑制剂的纯化及生物学特性分析
J Biol Chem. 1989 Jul 15;264(20):11966-73.
4
5
Tumor necrosis factor inhibitor: purification, NH2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities.肿瘤坏死因子抑制剂：纯化、氨基末端氨基酸序列及抗炎和免疫调节活性的证据
Eur J Immunol. 1990 May;20(5):1167-74. doi: 10.1002/eji.1830200533.
6
TNF inhibitor with a low molecular weight found in the human sera.在人血清中发现的低分子量肿瘤坏死因子抑制剂。
Tohoku J Exp Med. 1995 Dec;177(4):327-35. doi: 10.1620/tjem.177.327.
7
A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.第二种肿瘤坏死因子受体基因产物可释放一种天然存在的肿瘤坏死因子抑制剂。
Proc Natl Acad Sci U S A. 1990 Nov;87(21):8331-5. doi: 10.1073/pnas.87.21.8331.
8
Identification of tumor necrosis factor and lymphotoxin blocking factor(s) in the ascites of patients with advanced and recurrent ovarian cancer.晚期复发性卵巢癌患者腹水中肿瘤坏死因子和淋巴毒素阻断因子的鉴定。
Lymphokine Cytokine Res. 1991 Jun;10(3):225-9.
9
10
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 plasma levels in neonatal sepsis.新生儿败血症中肿瘤坏死因子-α、白细胞介素-1β和白细胞介素-6的血浆水平
Pediatr Res. 1993 Apr;33(4 Pt 1):380-3. doi: 10.1203/00006450-199304000-00013.
引用本文的文献
1
From supernatants to cytokines: a personal view on the early history of IL-1, IL-1Ra, TNF and its inhibitor in rheumatology.从上清液到细胞因子：我对风湿病领域中 IL-1、IL-1Ra、TNF 及其抑制剂早期历史的个人看法。
Arthritis Res Ther. 2018 May 30;20(1):101. doi: 10.1186/s13075-018-1607-y.
2
Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.靶向炎性细胞因子的生物制剂、临床应用及局限性
Int J Cell Biol. 2016;2016:9259646. doi: 10.1155/2016/9259646. Epub 2016 Dec 19.
3
Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.抗炎性肿瘤坏死因子阻断药物的药学方面
Inflammopharmacology. 2015 Jun;23(2-3):71-7. doi: 10.1007/s10787-015-0229-0. Epub 2015 Feb 17.
4
Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date.选择性肿瘤坏死因子抑制剂治疗中风和创伤性脑损伤的研究：迄今证据综述
Drug Des Devel Ther. 2014 Nov 7;8:2221-38. doi: 10.2147/DDDT.S67655. eCollection 2014.
5
Immune modulation in heart failure: past challenges and future hopes.心力衰竭中的免疫调节：过去的挑战与未来的希望。
Curr Heart Fail Rep. 2011 Mar;8(1):28-37. doi: 10.1007/s11897-010-0044-2.
6
Platelet-derived chemokines: pathophysiology and therapeutic aspects.血小板衍生趋化因子：病理生理学和治疗方面。
Cell Mol Life Sci. 2010 Jul;67(14):2363-86. doi: 10.1007/s00018-010-0306-x. Epub 2010 Mar 7.
7
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.中枢神经系统中的肿瘤坏死因子信号传导抑制：对正常脑功能和神经退行性疾病的影响。
J Neuroinflammation. 2008 Oct 17;5:45. doi: 10.1186/1742-2094-5-45.
8
Neutrophil-derived Oxidants and Proteinases as Immunomodulatory Mediators in Inflammation.中性粒细胞衍生的氧化剂和蛋白酶作为炎症中的免疫调节介质。
Mediators Inflamm. 1994;3(4):257-73. doi: 10.1155/S0962935194000360.
9
Tumor necrosis factor as a pharmacological target.肿瘤坏死因子作为一种药理学靶点。
Mol Biotechnol. 2005 Nov;31(3):239-44. doi: 10.1385/MB:31:3:239.
10
Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies.肿瘤坏死因子样弱凋亡诱导因子对人皮肤成纤维细胞和滑膜细胞的促炎活性：抗肿瘤坏死因子样弱凋亡诱导因子单克隆抗体的阻断和增强作用
Arthritis Res. 2002;4(2):126-33. doi: 10.1186/ar388. Epub 2001 Nov 9.
本文引用的文献
1
2
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.肿瘤坏死因子（恶病质素）是一种内源性热原，可诱导白细胞介素1的产生。
J Exp Med. 1986 Jun 1;163(6):1433-50. doi: 10.1084/jem.163.6.1433.
3
4
Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.肿瘤坏死因子和白细胞介素1：具有多种重叠生物学活性的细胞因子。
Lab Invest. 1987 Mar;56(3):234-48.
5
Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s).成纤维细胞和滑膜细胞产生前列腺素E2和胶原酶受尿源人白细胞介素1及抑制剂调控。
J Clin Invest. 1986 Oct;78(4):1120-4. doi: 10.1172/JCI112669.
6
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.恶病质素/肿瘤坏死因子可刺激人滑膜细胞和真皮成纤维细胞产生胶原酶和前列腺素E2。
J Exp Med. 1985 Dec 1;162(6):2163-8. doi: 10.1084/jem.162.6.2163.
7
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.肿瘤坏死因子与巨噬细胞分泌因子恶病质素的同一性。
Nature. 1985;316(6028):552-4. doi: 10.1038/316552a0.
8
Interleukin-1 inhibitors.白细胞介素-1抑制剂
Ann Inst Pasteur Immunol. 1987 May-Jun;138(3):486-8. doi: 10.1016/s0769-2625(87)80063-6.
9
A urine inhibitor of interleukin 1 activity that blocks ligand binding.一种可阻断配体结合的白细胞介素1活性的尿液抑制剂。
J Immunol. 1987 Sep 1;139(5):1546-9.
10
An endotoxin-induced serum factor that causes necrosis of tumors.一种由内毒素诱导产生的、可导致肿瘤坏死的血清因子。
Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70. doi: 10.1073/pnas.72.9.3666.
Zotero 插件